The Cosentyx Drug Market has witnessed exponential growth in recent years, driven by a confluence of factors shaping its trajectory. A significant market driver is the escalating prevalence of autoimmune diseases globally. Conditions such as psoriasis, psoriatic arthritis, and ankylosing spondylitis have become increasingly common, necessitating effective treatment options like Cosentyx. This innovative drug, developed by Novartis, has revolutionized the management of autoimmune disorders, thereby fueling demand and propelling market expansion.

The Global Cosentyx Drug Market is estimated to be valued at USD 5.32 Bn in 2024 and is expected to exhibit a CAGR of 7.3% over the forecast period 2024 to 2031. 

A comprehensive PEST analysis sheds light on the external factors influencing the Cosentyx Drug Market Size. Politically, regulatory frameworks governing drug approvals and healthcare policies profoundly impact market dynamics. Economic factors such as healthcare expenditure, insurance coverage, and pricing strategies significantly influence the accessibility and affordability of Cosentyx for patients. Socio-cultural aspects, including awareness about autoimmune diseases and patient preferences for advanced therapies, shape market demand. Additionally, technological advancements in drug delivery systems and manufacturing processes contribute to market growth.